바이오마커 시장 : 제공별, 유형별, 연구 분야별, 기술별, 질환별, 용도별 - 세계 예측(-2031년)

The global biomarkers market is expected to reach USD 112.10 billion by 2031 from USD 67.95 billion in 2026, at a CAGR of 10.5% from 2026 to 2031. This growth is driven by the increasing integration of artificial intelligence, digital pathology, and bioinformatics, as well as the rising adoption of precision medicine and companion diagnostics.

In 2025, the predictive biomarkers segment accounted for the largest share of the efficacy biomarkers market.

The biomarkers market is categorized by type into three segments: safety, efficacy, and validation biomarkers. The efficacy biomarkers segment is further divided into predictive, surrogate, pharmacodynamic, and prognostic biomarkers. In 2024, predictive biomarkers accounted for the largest share globally in the efficacy biomarkers segment. This dominance is primarily due to their crucial role in facilitating personalized treatment by identifying patients most likely to respond to specific therapies. This capability ultimately improves treatment outcomes and enhances clinical decision-making.

The use of predictive biomarkers has gained significant traction in fields such as oncology, autoimmune diseases, and infectious diseases. Additionally, the increasing number of companion diagnostic approvals for predictive biomarkers is driving market adoption. For instance, in June 2026, the FDA approved Roche's first companion diagnostic to assess the PTEN protein in prostate cancer. The VENTANA PTEN assay enables the identification of patients eligible for more targeted treatment decisions.

By technology, the immunoassays segment held the largest share of the biomarkers market in 2025.

The biomarkers market is divided into several technologies, including immunoassays, NGS (next-generation sequencing), PCR (polymerase chain reaction), mass spectrometry, chromatography, and others. In 2025, immunoassays are expected to hold the largest share of the biomarker market due to their high specificity and ability to detect a wide range of biomarkers across various disease areas, particularly in oncology, cardiology, and infectious diseases.

Immunoassays are favored for biomarker detection because they are compatible with both clinical diagnostics and research applications. Additionally, their scalability and automation capabilities enable high-throughput testing, which is essential for meeting the increasing demand for precision diagnostics.

Major companies are actively enhancing their immunoassay platforms to improve their diagnostic offerings. For instance, Roche provides the Elecsys Anti-p53 immunoassay for cancer diagnostics, while Abbott is expanding its ARCHITECT and Alinity immunoassay systems to test for infectious diseases and monitor chronic conditions.

APAC is the fastest-growing regional segment in the global biomarkers market from 2026 to 2031.

The biomarkers market is divided into several regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific region is expected to experience the highest CAGR during the forecast period. This growth is primarily driven by the expanding healthcare infrastructure in countries such as China, India, and Japan, along with increasing investments in precision medicine, genomic research, and diagnostic innovation.

The rising prevalence of chronic diseases, including cancer, cardiovascular disorders, metabolic diseases, and infectious diseases, is accelerating the demand for biomarker-based diagnostics and personalized treatment approaches. Additionally, the growth of clinical trial activities, the increasing adoption of companion diagnostics, supportive government initiatives for biotechnology and life sciences research, and the rapid integration of genomics, proteomics, and AI-enabled analytics are all contributing to the regional market growth.

Furthermore, expanding local biopharmaceutical manufacturing capabilities and improving regulatory frameworks are enhancing commercialization opportunities, establishing the Asia Pacific region as a significant hub for growth and innovation in the biomarkers market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (70%) and Demand Side (30%)
• By Designation: Managers (45%), CXO and Directors (30%), and Executives (25%)
• By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Companies Profiled in the Report

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Merck KGaA (Germany)
• Abbott (US)
• Thermo Fisher Scientific, Inc. (US)
• QIAGEN (Germany)
• Charles River Laboratories (US)
• Eurofins Scientific (Luxembourg)
• LabCorp (US)
• Revvity (US)
• bioMerieux (France)
• Guardant Health (US)
• JSR Corporation (Crown Biosciences) (Japan)
• Agilent Technologies, Inc. (US)
• Bio-Rad Laboratories (US)
• Illumina, Inc. (US)
• Quanterix (US)
• Meso Scale Diagnostics, LLC (US)
• Intertek Group Plc (UK)
• Meridian Bioscience (US)
• BioAgilytix Labs (US)
• R-Biopharm AG (Germany)
• Enzo Biochem (US)
• WuXi AppTec (China)
• Standard BioTools (US)
• Diatech Pharmacogenetics (Italy)
• Synexa Life Sciences BV (Netherlands)
• Proteome Sciences (UK)
• Pillar Biosciences (US)
• StressMarq Biosciences Inc. (Canada)
• Sebia (France)
• Bio-Techne (US)
• C2N Diagnostics (US)
• NorthEast Bioanalytical Laboratories (US)
• Signosis (US)
• Myriad Genetics, Inc. (US)

Research Coverage:

This research report categorizes the global biomarkers market by offering, type, research area, technology, disease indication, and end user.

The report provides comprehensive information about the key factors influencing the growth of the biomarkers market, including drivers, restraints, challenges, and opportunities. It also includes a detailed analysis of major industry players, offering insights into their business overviews, products, solutions, key strategies, collaborations, partnerships, and agreements. Additionally, the report covers new approvals and product launches, as well as recent collaborations, acquisitions, and developments within the global biomarkers market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of revenue numbers for the overall biomarkers market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their businesses more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (rising adoption of precision medicine and companion diagnostics, growing use of NGS, PCR, proteomics, and multi-omics platforms, increasing biomarker use in drug discovery and clinical trial design, rising burden of cancer, cardiovascular, neurological, and infectious diseases, expansion of liquid biopsy and minimally invasive biomarker testing, and increasing integration of AI, digital pathology, and bioinformatics), restraints (high cost of advanced biomarker discovery and validation and complex regulatory and reimbursement pathways), opportunities (co-development of biomarkers with targeted therapies and immunotherapies, expansion of blood-based biomarkers for oncology and neurology, growth in proteomics, spatial biology, and multi-omics biomarker discovery, and rising outsourcing of biomarker assay development and validation), and challenges (translating discovery biomarkers into clinically validated tests and patient heterogeneity and disease complexity)
• Product Development/Innovation: Detailed insights on upcoming technologies and research & development activities in the global biomarkers market
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the global biomarkers market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been conducted to provide insights into their strategies, product launches/approvals, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics for the global biomarkers market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 BIOMARKERS MARKET OVERVIEW
• 3.2 BIOMARKERS MARKET, BY TYPE & REGION
• 3.3 BIOMARKERS MARKET: GEOGRAPHIC SNAPSHOT

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising adoption of precision medicine and companion diagnostics
    • 4.2.1.2 Growing use of NGS, PCR, proteomics, and multi-omics platforms
    • 4.2.1.3 Increasing biomarker use in drug discovery and clinical trial design
    • 4.2.1.4 Rising burden of cancer, cardiovascular, neurological, and infectious diseases
    • 4.2.1.5 Expansion of liquid biopsy and minimally invasive biomarker testing
    • 4.2.1.6 Increasing integration of AI, digital pathology, and bioinformatics
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High cost of advanced biomarker discovery and validation
    • 4.2.2.2 Complex regulatory and reimbursement pathways

4.2.3 OPPORTUNITIES

• 4.2.3.1 Co-development of biomarkers with targeted therapies and immunotherapies
• 4.2.3.2 Expansion of blood-based biomarkers for oncology and neurology
• 4.2.3.3 Growth in proteomics, spatial biology, and multi-omics biomarker discovery
• 4.2.3.4 Rising outsourcing of biomarker assay development and validation
• 4.2.4 CHALLENGES
  • 4.2.4.1 Patient heterogeneity and disease complexity
  • 4.2.4.2 Translating discovery biomarkers into clinically validated tests
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL BIOMARKERS MARKET
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023-2025
  • 5.6.2 INDICATIVE SELLING PRICE OF CONSUMABLES, BY REGION, 2025
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA
  • 5.7.2 EXPORT DATA
  • 5.7.3 IMPORT VOLUME
  • 5.7.4 EXPORT VOLUME
• 5.8 KEY CONFERENCES & EVENTS, 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.10 INVESTMENT/FUNDING ACTIVITY
• 5.11 CASE STUDY ANALYSIS
• 5.12 IMPACT OF 2025 US TARIFFS ON BIOMARKERS MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON COUNTRY/REGION
    • 5.12.4.1 North America
    • 5.12.4.2 Europe
    • 5.12.4.3 Asia Pacific
  • 5.12.5 IMPACT ON END-USE INDUSTRIES
    • 5.12.5.1 Pharmaceutical & biotechnology companies
    • 5.12.5.2 Hospitals & diagnostic laboratories
    • 5.12.5.3 Academic & research institutes
    • 5.12.5.4 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY TECHNOLOGIES
    • 6.1.1.1 Immunoassays
    • 6.1.1.2 Next-generation sequencing (NGS)
    • 6.1.1.3 Polymerase chain reaction (PCR)
    • 6.1.1.4 In situ hybridization
    • 6.1.1.5 Microarrays
    • 6.1.1.6 Mass spectrometry
  • 6.1.2 ADJACENT TECHNOLOGIES
    • 6.1.2.1 Artificial intelligence (AI) and machine learning (ML)
    • 6.1.2.2 Sensors (wearable devices)
  • 6.1.3 COMPLEMENTARY TECHNOLOGIES
    • 6.1.3.1 Liquid biopsy
    • 6.1.3.2 CRISPR
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR BIOMARKER PATENTS, 2015-2025
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF AI/GEN AI ON BIOMARKERS MARKET
  • 6.5.1 TOP USE CASES & MARKET POTENTIAL
  • 6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET
  • 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
  • 6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET
• 6.6 SUCCESS STORIES & REAL-WORLD APPLICATIONS

7 SUSTAINABILITY & REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 REGULATORY FRAMEWORK
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
• 7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 BIOMARKERS MARKET, BY OFFERING

• 9.1 INTRODUCTION
• 9.2 CONSUMABLES
  • 9.2.1 ASSAY KITS
    • 9.2.1.1 Growing demand for assay kits in biomarker detection, quantification, and characterization to support growth
  • 9.2.2 REAGENTS & CHEMICALS
    • 9.2.2.1 Recurrent usage of reagents & chemicals in drug discovery and development to support demand
  • 9.2.3 OTHER CONSUMABLES
• 9.3 SERVICES
  • 9.3.1 GRADUAL TRANSITION FROM IN-HOUSE BIOMARKER TESTING TO OUTSOURCING SERVICES TO FUEL MARKET EXPANSION
• 9.4 SOFTWARE
  • 9.4.1 INCREASING ADOPTION OF BIOINFORMATICS TOOLS TO DRIVE MARKET GROWTH

10 BIOMARKERS MARKET, BY TYPE

• 10.1 INTRODUCTION
• 10.2 SAFETY BIOMARKERS
  • 10.2.1 WIDE APPLICATIONS OF SAFETY BIOMARKERS IN THERAPEUTIC AREAS & DEVELOPMENT TO BOOST MARKET GROWTH
• 10.3 EFFICACY BIOMARKERS
  • 10.3.1 PREDICTIVE BIOMARKERS
    • 10.3.1.1 Rising applications of biomarkers in personalized medicine to drive market
  • 10.3.2 SURROGATE BIOMARKERS
    • 10.3.2.1 Ability to serve as reliable indicators in place of clinical endpoints to support market growth
  • 10.3.3 PHARMACODYNAMIC BIOMARKERS
    • 10.3.3.1 Increasing utilization of pharmacodynamic biomarkers in biomarker and drug development to boost market
  • 10.3.4 PROGNOSTIC BIOMARKERS
    • 10.3.4.1 Increasing number of clinical trials to support growth of prognostic biomarkers
• 10.4 VALIDATION BIOMARKERS
  • 10.4.1 RISING RESEARCH FOR NEW DRUG DISCOVERY & DEVELOPMENT TO BOOST MARKET GROWTH

11 BIOMARKERS MARKET, BY RESEARCH AREA

• 11.1 INTRODUCTION
• 11.2 GENOMICS
  • 11.2.1 ADVANCEMENTS IN GENOMICS TECHNOLOGIES TO DRIVE SEGMENT GROWTH
• 11.3 PROTEOMICS
  • 11.3.1 GROWING PATIENT POPULATION WITH CHRONIC DISEASES TO DRIVE DEMAND
• 11.4 METABOLOMICS
  • 11.4.1 RISING INCIDENCE OF DIABETES AND OBESITY-RELATED CONDITIONS TO SUPPORT MARKET GROWTH
• 11.5 OTHER RESEARCH AREAS

12 BIOMARKERS MARKET, BY TECHNOLOGY

• 12.1 INTRODUCTION
• 12.2 IMMUNOASSAYS
  • 12.2.1 ELISA
    • 12.2.1.1 Extensive application of ELISA assays in clinical laboratories to support growth
  • 12.2.2 PROTEIN MICROARRAYS
    • 12.2.2.1 Quick and cost-effective nature of technology to support growth
  • 12.2.3 WESTERN BLOT
    • 12.2.3.1 Increasing investments in proteomics research to drive market
• 12.3 NEXT-GENERATION SEQUENCING (NGS)
  • 12.3.1 TECHNOLOGICAL ADVANCEMENTS IN NGS PLATFORMS TO SUPPORT GROWTH
• 12.4 POLYMERASE CHAIN REACTION (PCR)
  • 12.4.1 RAPID AND SENSITIVE DETECTION OF GENETIC BIOMARKERS TO DRIVE MARKET
• 12.5 MASS SPECTROMETRY
  • 12.5.1 INTEGRATION WITH OMICS TECHNOLOGIES TO DRIVE GROWTH

12.6 CHROMATOGRAPHY

• 12.6.1 GROWING UTILIZATION IN PROTEOMICS RESEARCH TO SUPPORT MARKET GROWTH
• 12.7 OTHER TECHNOLOGIES

13 BIOMARKERS MARKET, BY APPLICATION

• 13.1 INTRODUCTION
• 13.2 CLINICAL DIAGNOSTICS
  • 13.2.1 GROWING FOCUS ON EARLY DISEASE DETECTION AND DIAGNOSIS TO SUPPORT DEMAND
• 13.3 DRUG DISCOVERY & DEVELOPMENT
  • 13.3.1 INCREASING UTILIZATION OF BIOMARKERS IN DRUG DEVELOPMENT TO SUPPORT GROWTH
• 13.4 PERSONALIZED MEDICINE
  • 13.4.1 GROWING PREFERENCE FOR PRECISION THERAPEUTICS TO SUPPORT DEMAND
• 13.5 CLINICAL RESEARCH
  • 13.5.1 GROWING NUMBER OF CLINICAL TRIALS TO PROPEL MARKET
• 13.6 OTHER APPLICATIONS

14 BIOMARKERS MARKET, BY DISEASE INDICATION

• 14.1 INTRODUCTION
• 14.2 CANCER
  • 14.2.1 BREAST CANCER
    • 14.2.1.1 Expanding precision oncology and companion diagnostics to drive global growth in breast cancer biomarkers
  • 14.2.2 LUNG CANCER
    • 14.2.2.1 Expanding targeted therapies and rapid molecular profiling to drive global growth in lung cancer biomarkers
  • 14.2.3 COLORECTAL CANCER
    • 14.2.3.1 Expanding RAS/BRAF testing, liquid biopsy, and biomarker-linked targeted therapies to drive global
  • 14.2.4 PROSTATE CANCER
    • 14.2.4.1 Growth in HRR, PTEN, and liquid biopsy testing to accelerate biomarker adoption
  • 14.2.5 HEMATOLOGICAL CANCER
    • 14.2.5.1 Rising MRD monitoring and targeted hematology therapies to drive global growth in hematological cancer biomarkers
  • 14.2.6 OTHER CANCERS
• 14.3 INFECTIOUS DISEASES
  • 14.3.1 HIV/AIDS
    • 14.3.1.1 Expanding self-testing and viral load monitoring to drive global growth

14.3.2 HEPATITIS (B & C)

• 14.3.2.1 Rising hepatitis screening and automated immunoassay adoption to drive growth of HBV and HCV biomarkers
• 14.3.3 RESPIRATORY INFECTIONS
  • 14.3.3.1 Rising MRD monitoring and targeted hematology therapies to drive global growth in hematological cancer biomarkers
• 14.3.4 OTHER INFECTIOUS DISEASES
• 14.4 IMMUNOLOGICAL DISORDERS
  • 14.4.1 RHEUMATOID ARTHRITIS
    • 14.4.1.1 Earlier diagnosis and therapy-response stratification to drive growth in rheumatoid arthritis biomarkers
  • 14.4.2 INFLAMMATORY BOWEL DISEASE
    • 14.4.2.1 Non-invasive inflammation monitoring and targeted therapy management to drive growth in IBD biomarkers
  • 14.4.3 OTHER IMMUNOLOGICAL DISORDERS
• 14.5 NEUROLOGICAL DISORDERS
  • 14.5.1 ALZHEIMER'S DISEASE
    • 14.5.1.1 Growing demand for less-invasive alternatives to PET imaging and cerebrospinal fluid testing to boost market growth
  • 14.5.2 PARKINSON'S DISEASE
    • 14.5.2.1 Alpha-synuclein and digital biomarker advances to drive growth in Parkinson's disease biomarkers
  • 14.5.3 MULTIPLE SCLEROSIS
    • 14.5.3.1 Blood-based neurofilament light chain testing to strengthen growth in multiple sclerosis biomarkers
  • 14.5.4 OTHER NEUROLOGICAL DISORDERS
• 14.6 METABOLIC & ENDOCRINE DISORDERS
  • 14.6.1 DIABETES
    • 14.6.1.1 Continuous glucose-ketone monitoring and connected diabetes care to drive growth in diabetes biomarkers
  • 14.6.2 OBESITY
    • 14.6.2.1 GLP-1 therapy expansion and payer demand for response prediction to drive growth in obesity biomarkers
  • 14.6.3 OTHER METABOLIC & ENDOCRINE DISORDERS
• 14.7 CARDIOVASCULAR DISORDERS
  • 14.7.1 CONTINUOUS INNOVATION IN CARDIAC BIOMARKERS TO BOOST MARKET GROWTH
• 14.8 OTHER DISEASE INDICATIONS

15 BIOMARKERS MARKET, BY END USER

• 15.1 INTRODUCTION
• 15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 15.2.1 GROWING MARKET STRATEGIES BY KEY PLAYERS TO SUPPORT MARKET GROWTH

15.3 HOSPITALS & DIAGNOSTIC LABORATORIES

• 15.3.1 VITAL ROLE OF BIOMARKERS AS BIOLOGICAL INDICATORS IN DIAGNOSIS OF DISEASES TO FUEL MARKET GROWTH
• 15.4 ACADEMIC & RESEARCH INSTITUTES
  • 15.4.1 INCREASING FUNDING ACTIVITIES TO DRIVE MARKET
• 15.5 OTHER END USERS

16 BIOMARKERS MARKET, BY REGION

• 16.1 INTRODUCTION
• 16.2 NORTH AMERICA
  • 16.2.1 US
    • 16.2.1.1 Rising focus on biopharma research to support growth
  • 16.2.2 CANADA
    • 16.2.2.1 Increasing incidence of cancer to drive biomarkers market growth
• 16.3 EUROPE
  • 16.3.1 GERMANY
    • 16.3.1.1 Growth in biopharmaceutical R&D activities to propel growth
  • 16.3.2 UK
    • 16.3.2.1 Government funding and strategic collaborations with biotech firms to boost adoption of biomarkers
  • 16.3.3 FRANCE
    • 16.3.3.1 Increasing government investment for proteomics & genomics research to drive growth
  • 16.3.4 ITALY
    • 16.3.4.1 Increasing developments in life science research to fuel growth
  • 16.3.5 SPAIN
    • 16.3.5.1 R&D initiatives for personalized medicine to support market growth
  • 16.3.6 REST OF EUROPE
• 16.4 ASIA PACIFIC
  • 16.4.1 CHINA
    • 16.4.1.1 Rising incidence of CVD to propel market
  • 16.4.2 JAPAN
    • 16.4.2.1 Strong regulatory guidelines for drug discovery & development to support market growth
  • 16.4.3 INDIA
    • 16.4.3.1 Favorable scenario for FDI and increasing number of clinical trials to propel market
  • 16.4.4 SOUTH KOREA
    • 16.4.4.1 Increasing innovations in NGS technologies to support market growth
  • 16.4.5 AUSTRALIA
    • 16.4.5.1 Increasing demand for diagnostic solutions to propel market
  • 16.4.6 REST OF ASIA PACIFIC

16.5 LATIN AMERICA

• 16.5.1 BRAZIL
  • 16.5.1.1 Increased government investments in pharmaceutical R&D to drive market
• 16.5.2 MEXICO
  • 16.5.2.1 Rising demand for chronic disease treatment to support market growth
• 16.5.3 REST OF LATIN AMERICA
• 16.6 MIDDLE EAST
  • 16.6.1 GCC COUNTRIES
    • 16.6.1.1 Saudi Arabia
      • 16.6.1.1.1 Growing healthcare expenditure to boost market growth
    • 16.6.1.2 UAE
      • 16.6.1.2.1 Increasing collaborative efforts for pharmaceutical R&D to drive growth
    • 16.6.1.3 Rest of GCC countries
  • 16.6.2 REST OF MIDDLE EAST
• 16.7 AFRICA
  • 16.7.1 INCREASING DEMAND FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET

17 COMPETITIVE LANDSCAPE

• 17.1 OVERVIEW
• 17.2 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOMARKERS MARKET, 2023-2026
• 17.3 REVENUE ANALYSIS, 2023-2025
• 17.4 MARKET SHARE ANALYSIS, 2025
• 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 17.5.1 STARS
  • 17.5.2 EMERGING LEADERS
  • 17.5.3 PERVASIVE PLAYERS
  • 17.5.4 PARTICIPANTS
  • 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 17.5.5.1 Company footprint
    • 17.5.5.2 Region footprint
    • 17.5.5.3 Offering footprint
    • 17.5.5.4 Technology footprint
    • 17.5.5.5 Application footprint
• 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 17.6.1 PROGRESSIVE COMPANIES
  • 17.6.2 RESPONSIVE COMPANIES
  • 17.6.3 DYNAMIC COMPANIES
  • 17.6.4 STARTING BLOCKS
  • 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 17.6.5.1 Detailed list of key startups/SME players
    • 17.6.5.2 Competitive benchmarking of key startups/SME players
• 17.7 COMPANY VALUATION & FINANCIAL METRICS
  • 17.7.1 FINANCIAL METRICS
  • 17.7.2 COMPANY VALUATION
• 17.8 BRAND/PRODUCT COMPARISON
• 17.9 COMPETITIVE SCENARIO
  • 17.9.1 PRODUCT LAUNCHES & APPROVALS
  • 17.9.2 DEALS
  • 17.9.3 EXPANSIONS

18 COMPANY PROFILES

• 18.1 KEY PLAYERS
  • 18.1.1 F. HOFFMANN-LA ROCHE LTD.
    • 18.1.1.1 Business overview
    • 18.1.1.2 Products & services offered
    • 18.1.1.3 Recent developments
      • 18.1.1.3.1 Product launches & approvals
      • 18.1.1.3.2 Deals
    • 18.1.1.4 MnM view
      • 18.1.1.4.1 Right to win
      • 18.1.1.4.2 Strategic choices
      • 18.1.1.4.3 Weaknesses & competitive threats
  • 18.1.2 DANAHER CORPORATION
    • 18.1.2.1 Business overview
    • 18.1.2.2 Products offered
    • 18.1.2.3 MnM view
      • 18.1.2.3.1 Right to win
      • 18.1.2.3.2 Strategic choices
      • 18.1.2.3.3 Weaknesses & competitive threats
  • 18.1.3 ILLUMINA, INC.
    • 18.1.3.1 Business overview
    • 18.1.3.2 Products & services offered
    • 18.1.3.3 Recent developments
      • 18.1.3.3.1 Product launches & approvals
      • 18.1.3.3.2 Deals
    • 18.1.3.4 MnM view
      • 18.1.3.4.1 Right to win
      • 18.1.3.4.2 Strategic choices
      • 18.1.3.4.3 Weaknesses & competitive threats

18.1.4 MERCK KGAA

• 18.1.4.1 Business overview
• 18.1.4.2 Products & services offered
• 18.1.4.3 Recent developments
  • 18.1.4.3.1 Deals
  • 18.1.4.3.2 Expansions
• 18.1.4.4 MnM view
  • 18.1.4.4.1 Right to win
  • 18.1.4.4.2 Strategic choices
  • 18.1.4.4.3 Weaknesses & competitive threats
• 18.1.5 THERMO FISHER SCIENTIFIC INC.
  • 18.1.5.1 Business overview
  • 18.1.5.2 Products & services offered
  • 18.1.5.3 Recent developments
    • 18.1.5.3.1 Product approvals
    • 18.1.5.3.2 Deals
    • 18.1.5.3.3 Expansions
  • 18.1.5.4 MnM view
    • 18.1.5.4.1 Right to win
    • 18.1.5.4.2 Strategic choices
    • 18.1.5.4.3 Weaknesses & competitive threats
• 18.1.6 QIAGEN
  • 18.1.6.1 Business overview
  • 18.1.6.2 Products & services offered
  • 18.1.6.3 Recent developments
    • 18.1.6.3.1 Product launches
    • 18.1.6.3.2 Deals
    • 18.1.6.3.3 Expansions
• 18.1.7 ABBOTT
  • 18.1.7.1 Business overview
  • 18.1.7.2 Products & services offered
  • 18.1.7.3 Recent developments
    • 18.1.7.3.1 Product approvals
    • 18.1.7.3.2 Deals
• 18.1.8 AGILENT TECHNOLOGIES, INC.
  • 18.1.8.1 Business overview
  • 18.1.8.2 Products & services offered
  • 18.1.8.3 Recent developments
    • 18.1.8.3.1 Product approvals
    • 18.1.8.3.2 Deals

18.1.9 REVVITY INC.

• 18.1.9.1 Business overview
• 18.1.9.2 Products & services offered
• 18.1.9.3 Recent developments
  • 18.1.9.3.1 Product launches
• 18.1.10 CHARLES RIVER LABORATORIES
  • 18.1.10.1 Business overview
  • 18.1.10.2 Products & services offered
  • 18.1.10.3 Recent developments
    • 18.1.10.3.1 Deals
• 18.1.11 BIO-RAD LABORATORIES, INC.
  • 18.1.11.1 Business overview
  • 18.1.11.2 Products & services offered
  • 18.1.11.3 Recent developments
    • 18.1.11.3.1 Product launches
    • 18.1.11.3.2 Deals
• 18.1.12 EUROFINS SCIENTIFIC
  • 18.1.12.1 Business overview
  • 18.1.12.2 Products & services offered
  • 18.1.12.3 Recent developments
    • 18.1.12.3.1 Deals
• 18.1.13 BIOMERIEUX
  • 18.1.13.1 Business overview
  • 18.1.13.2 Products & services offered
  • 18.1.13.3 Recent developments
    • 18.1.13.3.1 Product approvals
    • 18.1.13.3.2 Deals
    • 18.1.13.3.3 Expansions
• 18.1.14 JSR CORPORATION
  • 18.1.14.1 Business overview
  • 18.1.14.2 Products & services offered
  • 18.1.14.3 Recent developments
    • 18.1.14.3.1 Deals
• 18.1.15 GUARDANT HEALTH
  • 18.1.15.1 Business overview
  • 18.1.15.2 Products & services offered
  • 18.1.15.3 Recent developments
    • 18.1.15.3.1 Product approvals
    • 18.1.15.3.2 Deals
• 18.1.16 LABCORP
  • 18.1.16.1 Business overview
  • 18.1.16.2 Products & services offered
  • 18.1.16.3 Recent developments
    • 18.1.16.3.1 Product launches
• 18.1.17 QUANTERIX
  • 18.1.17.1 Business overview
  • 18.1.17.2 Products & services offered
  • 18.1.17.3 Recent developments
    • 18.1.17.3.1 Product launches
    • 18.1.17.3.2 Deals
• 18.1.18 MESO SCALE DIAGNOSTICS, LLC
  • 18.1.18.1 Business overview
  • 18.1.18.2 Products & services offered
• 18.1.19 SIEMENS HEALTHINEERS AG
  • 18.1.19.1 Business overview
  • 18.1.19.2 Products offered
• 18.2 OTHER PLAYERS
  • 18.2.1 CELERION
  • 18.2.2 STANDARD BIOTOOLS
  • 18.2.3 SEBIA
  • 18.2.4 BIOAGILYTIX LABS
  • 18.2.5 STRESSMARQ BIOSCIENCES INC.
  • 18.2.6 NORTHEAST BIOANALYTICAL LABORATORIES LLC
  • 18.2.7 SIGNOSIS
  • 18.2.8 SERIMMUNE
  • 18.2.9 THERAINDX LIFESCIENCES PVT. LTD.
  • 18.2.10 SYNEXA LIFE SCIENCES BV
  • 18.2.11 DIATECH PHARMACOGENETICS
  • 18.2.12 PILLAR BIOSCIENCES
  • 18.2.13 R-BIOPHARM AG

19 RESEARCH METHODOLOGY

• 19.1 RESEARCH DATA
  • 19.1.1 SECONDARY DATA
  • 19.1.2 PRIMARY DATA
• 19.2 MARKET ESTIMATION METHODOLOGY
  • 19.2.1 INSIGHTS OF PRIMARY EXPERTS
  • 19.2.2 TOP-DOWN APPROACH
• 19.3 MARKET GROWTH RATE FORECAST
• 19.4 MARKET BREAKDOWN & DATA TRIANGULATION
• 19.5 RESEARCH ASSUMPTIONS
• 19.6 RESEARCH LIMITATIONS
• 19.7 RISK ASSESSMENT

20 APPENDIX

• 20.1 DISCUSSION GUIDE
• 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 20.3 CUSTOMIZATION OPTIONS
• 20.4 RELATED REPORTS
• 20.5 AUTHOR DETAILS